indigotindisulfonate sodium (Bludigo) Report issue

Small molecule Imaging Approved FDA
AACT ChEMBL Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: O=C1/C(=C2\Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21.[Na+].[Na+]
  • InChIKey: KHLVKKOJDHCJMG-QDBORUFSSA-L
  • Mol. Mass: 466.36
  • ALogP: 1.31
  • ChEMBL Molecule:
    indigotindisulfonate sodium  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$142.2860
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

indigo carmine | indigotindisulfonate sodium | sodium indigotindisulfonate

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Vision, Ocular (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Brain Neoplasms (Phase 1/Phase 2)

Colonic Polyps (Phase 1)

Ureteral Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue